Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

Koola MM, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Warren KR, Feldman S, Shim JC, Love RC, Kelly DL.

J Psychiatr Res. 2012 Aug;46(8):987-93. doi: 10.1016/j.jpsychires.2012.04.019. Epub 2012 May 16.

2.

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE.

Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192.

PMID:
20124114
3.

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.

Zuddas A, Zanni R, Usala T.

Eur Neuropsychopharmacol. 2011 Aug;21(8):600-20. doi: 10.1016/j.euroneuro.2011.04.001. Epub 2011 May 6. Review.

PMID:
21550212
4.

Lifetime prevalence of psychotic and bipolar I disorders in a general population.

Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J.

Arch Gen Psychiatry. 2007 Jan;64(1):19-28.

PMID:
17199051
5.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

6.

Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review.

Baker AL, Hides L, Lubman DI.

J Clin Psychiatry. 2010 Mar;71(3):247-54. doi: 10.4088/JCP.09r05119gry. Review.

PMID:
20331929
7.

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.

Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C.

Eur Neuropsychopharmacol. 2011 Aug;21(8):621-45. doi: 10.1016/j.euroneuro.2010.07.002. Epub 2010 Aug 10. Review.

PMID:
20702068
8.

Circadian rhythms and clock genes in psychotic disorders.

Lamont EW, Coutu DL, Cermakian N, Boivin DB.

Isr J Psychiatry Relat Sci. 2010;47(1):27-35. Review.

9.

Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people.

Fraser S, Hides L, Philips L, Proctor D, Lubman DI.

Schizophr Res. 2012 Apr;136(1-3):110-5. doi: 10.1016/j.schres.2012.01.022. Epub 2012 Feb 7.

PMID:
22321667
10.

Cannabis use and psychotic disorders: an update.

Hall W, Degenhardt L, Teesson M.

Drug Alcohol Rev. 2004 Dec;23(4):433-43. Review.

PMID:
15763748
11.

Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.

Stip E, Zhornitsky S, Moteshafi H, Létourneau G, Stikarovska I, Potvin S, Tourjman V.

Clin Ther. 2011 Dec;33(12):1853-67. doi: 10.1016/j.clinthera.2011.10.027. Epub 2011 Dec 1. Review.

PMID:
22133697
12.

Treatment adherence therapy in people with psychotic disorders: randomised controlled trial.

Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW, Loonen AJ, Mulder CL.

Br J Psychiatry. 2010 Dec;197(6):448-55. doi: 10.1192/bjp.bp.110.077289.

13.

[Motivational interviewing for cannabis users with psychotic disorders].

Bonsack C, Montagrin Y, Favrod J, Gibellini S, Conus P.

Encephale. 2007 Oct;33(5):819-26. French.

PMID:
18357854
15.

Family therapy for schizophrenia: co-occurring psychotic and substance use disorders.

Gottlieb JD, Mueser KT, Glynn SM.

J Clin Psychol. 2012 May;68(5):490-501. doi: 10.1002/jclp.21852. Epub 2012 Apr 12.

PMID:
22498950
16.

Immigration, social environment and onset of psychotic disorders.

Bourque F, van der Ven E, Fusar-Poli P, Malla A.

Curr Pharm Des. 2012;18(4):518-26. Review.

PMID:
22239583
17.

Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications.

Aggarwal M, Banerjee A, Singh SM, Mattoo SK, Basu D.

Asian J Psychiatr. 2012 Sep;5(3):220-4. doi: 10.1016/j.ajp.2011.11.008. Epub 2012 Mar 6.

PMID:
22981049
18.

[Psychotic disorders related with chronic use of mephedrone. Case report].

Urban M, Rudecki T, Wróblewski D, Rabe-Jabłońska J.

Psychiatr Pol. 2011 May-Jun;45(3):431-7. Polish.

PMID:
22232972
19.

Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study.

Lewandowski KE, DePaola J, Camsari GB, Cohen BM, Ongür D.

Ann Acad Med Singapore. 2009 May;38(5):383-5.

20.

Acting on harmful command hallucinations in psychotic disorders: an integrative approach.

Shawyer F, Mackinnon A, Farhall J, Sims E, Blaney S, Yardley P, Daly M, Mullen P, Copolov D.

J Nerv Ment Dis. 2008 May;196(5):390-8. doi: 10.1097/NMD.0b013e318171093b.

PMID:
18477881

Supplemental Content

Support Center